Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: OpGen, DNA 2.0, MDxHealth, and More

NEW YORK (GenomeWeb) – OpGen this week announced that it issued approximately 3.6 million shares of its common stock in the fourth quarter under its previously announced "at the market offering" program. The program has resulted in net proceeds of approximately $4.6 million, which will be used to support OpGen's research, development, and manufacturing of product candidates, and for other general corporate purposes.

DNA 2.0 said this week that it has changed its name to ATUM, reflecting its expanded focus on manipulating DNA in order to build better genes, proteins, pathways and cells.

MDxHealth said this week that its laboratory in Nijmegen, The Netherlands has received ISO 13485:2016 certification for the design, development, manufacture, and distribution of in vitro molecular diagnostic products, as well as client services and service testing for oncological diseases.

NantHealth announced this week that it has been selected for inclusion in the Nasdaq Biotechnology Index, effective Dec. 19. The Index tracks the performance of securities listed on the Nasdaq that are classified as either biotechnology or pharmaceutical. Opko Health and Editas Medicine were also added to the Nasdaq Biotech this week.

Oxford BioDynamics this week was admitted to the London Stock Exchange-operated AIM market for trading of its ordinary shares. The share placement has raised gross proceeds of £20 million ($25 million), £7.1 million of which was allocated to the company.

Asklepios Clinics Founder and sole shareholder Bernard große Broermann this week assumed a 40 percent share in the Center for Metagenomics (CeMeT). Specific details of the investment were not disclosed, but the company noted that CeMeT's capital has been increased by several million euros. CeMeT's founding shareholders, Ingo Autenrieth, Daniel Huson, and Detlef Weigel, together hold 55.6 percent of the firm's shares.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.